Pro-Pharmaceuticals, Inc. Release: New Data Shows DAVANAT(R) Extends Survival of End-Stage Colorectal Cancer Patients More Than 6 Months

NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW), today announced that new data of 14 end-stage colorectal cancer patients from its Phase II trial showed that DAVANAT® extended median survival by more than six months. The Company tracked these patients and gathered data after they left the trial. The patients entered the trial with disease that progressed despite previously being treated with standard chemotherapies and biologics such as AVASTIN® and/or ERBITUX®.